| Literature DB >> 35015848 |
Sohila M Elonsy1, Miranda F Kamal1, Mohamed M A Hamdy2, Mona M Abdel Moneim2.
Abstract
BACKGROUND: The antiviral drug GS-5734 remdesivir is a new phosphoramidate prodrug developed initially as a treatment for Ebola virus which then proved to have antiviral properties against other viruses. After clinical trials, it was the first antiviral to be approved by the U.S. Food and Drug Administration in 2020 to treat severe coronavirus (COVID-19) cases. The widespread current pandemic gave an urge to its fast production and marketing. Thus, new analytical methods must be available for its analysis in a fast and easy manner with low cost to be applicable in all laboratories.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35015848 PMCID: PMC9383131 DOI: 10.1093/jaoacint/qsac001
Source DB: PubMed Journal: J AOAC Int ISSN: 1060-3271 Impact factor: 2.028
Figure 1.Chemical structure and UV absorption spectrum of RD.
Figure 2.MEKC electropherogram of a standard solution containing 10 µg/mL RD at 245 nm.
Analytical parameters for determination of remdesivir using the proposed MEKC-DAD method
| Parameter | Value |
|---|---|
| Wavelength, nm | 245 |
| Concentration range, μg/mL | 1–50 |
| Intercept (a) | –0.768 |
| Sa | 0.528 |
| Slope (b) | 2.179 |
| Sb | 0.019 |
| RSD, %, of the slope (Sb%) | 0.863 |
| Correlation coefficient (r) | 0.9998 |
| Sy/x | 0.851 |
| F | 13418.733 |
| Significance F | 9.092 × 10–10 |
| LOD, μg/mL | 0.289 |
| LOQ, μg/mL | 0.963 |
Standard deviation of the intercept.
Standard deviation of the slope.
Standard deviation of residuals.
Variance ratio, equals the mean of squares due to regression divided by the mean of squares about regression (due to residuals).
Figure 3.Calibration and residuals plot of the regression data of RD at 245 nm.
Precision and accuracy for determination of remdesivir in bulk using the proposed MEKC-DAD method
| Nominal value of RD, μg/mL | Found ± SD | RSD, % | Mean recovery, % | Er, % |
|---|---|---|---|---|
| Within-day | ||||
| 5 | 4.927 ± 0.096 | 1.948 | 98.540 | –1.460 |
| 20 | 19.691 ± 0.280 | 1.422 | 98.455 | –1.545 |
| 50 | 50.077 ± 0.955 | 1.907 | 100.154 | 0.154 |
| Between-days | ||||
| 5 | 5.003 ± 0.096 | 1.919 | 100.060 | 0.060 |
| 20 | 19.753 ± 0.312 | 1.580 | 98.765 | –1.235 |
| 50 | 50.536 ± 0.701 | 1.387 | 101.072 | 1.072 |
Mean ± SD for three determinations.
% Relative standard deviation.
% Relative error.
Figure 4.(a) Absorption spectrum of 10 μg/mL RD sample (from commercial injection solution) measured at different time intervals across the peak and (b) the purity plot for the RD peak.
Robustness evaluation for the analysis of remdesivir using the proposed MEKC-DAD method
| Method parameter | Robustness parameter | |||
|---|---|---|---|---|
| Peak area ± SD | RSD, % | Migration time ± SD | RSD, % | |
| Buffer concentration 20 ± 2 mM | 20.167 ± 0.153 | 0.759 | 5.247 ± 0.050 | 0.953 |
| Buffer pH 9 ± 0.2 | 20.233 ± 0.379 | 1.873 | 5.277 ± 0.100 | 1.895 |
| SDS concentration 25 ± 2 mM | 20.100 ± 0.300 | 1.493 | 5.330 ± 0.108 | 2.026 |
| Wavelength 245 ± 2 nm | 20.267 ± 0.252 | 1.243 | — | |
Robustness parameters were determined for a sample containing 10 µg/mL of RD.
— = Not applicable.
Figure 5.MEKC electropherogram of a sample obtained from the injection vial of RD at 10 μg/mL at 245 nm.
Figure 6.(a) Green certificate, (b) GAPI assessment, (c) AGREE score, and (d) NEMI pictogram of the proposed MEKC method for the RD assay.